MedPath

Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

Completed
Conditions
Crow's Feet Lines
Lateral Canthal Lines
Registration Number
NCT02248844
Lead Sponsor
Allergan
Brief Summary

This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
667
Inclusion Criteria
  • Subject and Investigator decision to treat crow's feet lines with Botox®
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Participants with Adverse EventsUp to 3 months
Secondary Outcome Measures
NameTimeMethod
Investigator's Assessment of Change in Appearance of Crow's Feet Lines on a 3-Point ScaleBaseline, Up to 3 months
Subject's Assessment of Change in Appearance of Crow's Feet Lines on a 7-Point ScaleBaseline, Up to 3 months

Trial Locations

Locations (1)

Dr. Robbin Clinic

🇰🇷

Gangnam-gu, Seoul, Korea, Republic of

Dr. Robbin Clinic
🇰🇷Gangnam-gu, Seoul, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.